Perrigo inks $540M deal for Paddock Labs; Famar to buy Sanofi plant in Madrid;

 @FiercePharma: Former Merck rep wins $555K in retaliation suit. Report | Follow @FiercePharma

> Store-brand drugmaker Perrigo has agreed to buy the assets of generics maker Paddock Laboratories for $540 million. News

> Greek pharma Famar plans to acquire a Sanofi-Aventis plant in Madrid to expand its sterile dose manufacturing capabilities and capacity; all employees will be retained by Famar and Sanofi will continue to source some products there. Story

> India's Dr Reddy's Laboratories has launched a generic version of the blockbuster stomach-acid drug Protonix in the U.S.; marketed by Pfizer, the drug lost patent protection this month. Article | Report

> Danish drugmaker Novo Nordisk said it will appeal a U.S. court ruling that found the patent on its combination diabetes drug PrandiMet to be invalid, a decision that could open the door to generic competition. Item

> A federal appellate court has ruled that a consumer lawsuit against KV Pharmaceutical may go forward, reviving a suit that claims the drugmaker put an adulterated hypertension drug on the market. Report 

> Krka Group, Slovenia's biggest drugmaker, will likely report revenue of more than 1 billion euros ($1.35 billion) for the first time with a drop in profit from last year's business, Finance reported, citing analysts' estimates. Story

> An association representing small to medium U.K. pharma companies says the forthcoming Cancer Drugs Fund is welcome-- but must not distort National Health Service priorities or be a pilot for a new pricing system for all drugs. Article

> The U.S. Supreme Court questioned a federal judge's decision to bar a group of West Virginia plaintiffs from proceeding with a class-action lawsuit over Bayer's cholesterol-lowering drug Baycol, which was withdrawn from the U.S. market in 2001. Report

Biotech News

 @FierceBiotech: Pfizer, Theraclone ink $632 R&D deal for cancer, infectious disease. News | Follow @FierceBiotech

> Bleeding risk torpedoed Merck's blockbuster vorapaxar study. Article

> MannKind slammed with FDA demand for new Afrezza trials. Item 

> Termeer counsels patience on Sanofi bid. News 

> Protalix boasts of "revolutionary" advance on oral Gaucher's drug. Report 

> Vertex wins an expedited review of telaprevir app. Story 

Vaccines News

> Fiocruz granted royalty-bearing license from iBio. Story

> WHO's Chan sees anti-vaccine sentiment as "worrisome trend." News

> Nanoparticle vax could prevent stomach flu. Article

> H1N1 provides new universal flu vax hope. Report

> RecipharmCobra oral TB vax produces good immune response. News

Manufacturing News

> Ops strength adds to Dr. Reddy's momentum. Article

> Process greening at Pfizer began with Viagra. News

> Pharma holds lead in cargo theft categories. Story

> Deltex consents; will recall and destroy drugs. Item

> Hospira plots to block anesthetic from executions. Report

> Deadly glycol contamination case delayed again. Article

And Finally... While U.S. lawmakers re-debate healthcare reform, U.K. officials are considering a bill that would overhaul the National Health Service to put doctors in charge of allocating healthcare dollars. Item | Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.